RDUS Radius Health Inc.

34.60
-0.01  -0%
Previous Close 34.61
Open 34.39
Price To book 7.25
Market Cap 1505247050
Shares 43,504,250
Volume 1,890,734
Short Ratio 10.99
Av. Daily Volume 940,647

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 2H 2017.
Elacestrant
Vasomotor symptoms
PDUFA date originally scheduled for March 30 2017 delayed by three months to June 30, 2017. Approval announced April 28, 2017.
TYMLOS (Abaloparatide)
Osteoporosis

Latest News

  1. Radius Health Receives FDA Fast Track Designation for Elacestrant (RAD1901)
  2. Radius Health, Inc. – Value Analysis (NASDAQ:RDUS) : October 13, 2017
  3. Radius Health to Present First Health Economics Data on TYMLOS™ (abaloparatide) Injection at the Academy of Managed Care Pharmacy Nexus 2017
  4. Radius Health, Inc. breached its 50 day moving average in a Bearish Manner : RDUS-US : October 12, 2017
  5. Radius Health to Announce Third Quarter 2017 Financial Results, Host Conference Call and Live Webcast on November 2, 2017
  6. See what the IHS Markit Score report has to say about Radius Health Inc.
  7. Radius (RDUS) Enrols First Patient in Breast Cancer Study
  8. Radius Health Initiates Phase 1 Clinical Trial of RAD140 for the Treatment of Hormone Receptor Positive Breast Cancer
  9. Radius Health, Inc. breached its 50 day moving average in a Bullish Manner : RDUS-US : September 28, 2017
  10. Radius Health to Present at Cantor Annual Global Healthcare Conference
  11. Radius Health Inc (RDUS) President and CEO Jesper Hoiland Bought $199,592 of Shares
  12. Radius Health Presents Positive Data for TYMLOS™ (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR 2017 Annual Meeting
  13. Radius Health to Present at Morgan Stanley 15th Annual Global Healthcare Conference
  14. Radius Health (RDUS) Down 12.7% Since Earnings Report: Can It Rebound?
  15. Radius Health to Present Eight Abstracts at the American Society of Bone and Mineral Research (ASBMR) 2017 Annual Meeting Including Results of the ACTIVE and ACTIVExtend Trials for TYMLOS™ (abaloparatide) Injection
  16. Radius Health, Inc. – Value Analysis (NASDAQ:RDUS) : August 19, 2017
  17. Today's Research Reports on Stocks to Watch: Radius Health, Inc. and Community Health Systems